Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with peripheral T-cell lymphoma (a type of lymphoma that affects T cells) of certain subtypes.
- Your cancer has come back or not responded after at least one prior treatment, and you have had no more than three prior treatments.
- You have a tumor that can be measured on a CT scan and is at least 1.5 cm in size.
- Your blood counts and organ function are within certain limits as determined by blood tests.
- You must not have certain infections like HIV, active hepatitis B or C, or an active infection requiring IV treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
Hear when a new Peripheral T-Cell Lymphoma, Not Otherwise Specified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.